For medically inoperable early-stage nonsmall cell lung cancer (NSCLC) patients, stereotactic body radiotherapy (SBRT) is the emerging treatment of choice. SBRT differs from conventional radiotherapy (RT) in that large doses of radiation are employed over a few (usually fewer than five, but sometimes up to 10) fractions to radioablate the tumour. Safe delivery of such profoundly damaging doses requires highly precise RT, in conjunction with image guidance and careful treatment planning.
Several prospective clinical trials have confirmed the feasibility, safety and efficacy of SBRT, consistently reporting local control rates of 80-95%, comparable to surgical resection [1] [2] [3] , although assessment of response is more complicated than it is following surgery [3] . Radiographic changes following SBRT differ from those following conventional RT, suggesting a unique histological response, and characterisation of these changes is a clinical challenge. Little is known of the histology of local recurrence following SBRT, since medically inoperable patients who fail locally cannot be salvaged surgically. Fineneedle aspiration biopsy provides only cytological information and is subject to false-negative results, while very frail patients may not even be able to tolerate the biopsy. Without histological confirmation, local failure (LF) is a clinical rather than a pathological diagnosis. In this report, we review our experience of four patients originally treated with SBRT who were salvaged surgically for their presumed LF.
From October 2004 to December 2010, we treated 209 patients with early (T1-2N0M0) NSCLC using SBRT on a prospective institution research ethics board-approved protocol. All patients were deemed medically inoperable by an experienced c EUROPEAN RESPIRATORY JOURNAL VOLUME 39 NUMBER 4 thoracic surgeon, typically due to medical comorbidities. Standard staging investigations included 2-fluoro-2-deoxy-Dglucose (FDG)-positron emission tomography (PET). Our SBRT technique has previously been described [4, 5] . Patients underwent post-treatment PET-computed tomography (CT) and serial CT scans as per our protocol.
Cases in which there was high clinical suspicion for LF were discussed at our weekly rounds. Further investigations (including repeat PET-CT and/or biopsy) were requested accordingly and cases were also presented for discussion at our multidisciplinary conference.
Of the 209 patients treated, we identified six cases with local progression (3-yr local control 94.6%). In four of these instances, the local progression represented the only known site of disease. While all four of these patients had initially been deemed medically inoperable at the time of initial diagnosis, they were all considered fit for surgery at the time of presumed post-SBRT failure (table 1) . The initial reasons for inoperability in these four patients included comorbidities, such as recent coronary event, cerebrovascular event, severe pulmonary disease or other medical illnesses such as diabetes. Improvement or stabilisation of comorbidities after SBRT eventually allowed these patients to undergo major pulmonary resection.
Although an initial reduction in the maximum standardised uptake value (SUV) of the tumour was seen in three out of these four patients after SBRT, the maximum response on CT never exceeded stable disease as per Response Evaluation Criteria in Solid Tumors (RECIST). In fact, at the 3-month mark, two patients already had growth of the index lesion that fulfilled the criteria for progressive disease. All patients had a growing mass lesion at the treated site on serial CT imaging, which prompted further investigations. Isolated LF was declared based on clinical and/or pathological evidence.
For patient A, there was a small initial regression on post-SBRT scans; however, the mass then grew to 4 cm before a positive biopsy. Patient B's tumour, conversely, demonstrated growth on imaging, but two biopsies returned negative before the third one revealed malignancy. Patient C's tumour grew until it was twice as large as the initially treated primary. Repeat PET was not carried out since the initial tumour was not FDGavid (SUV51.0) and the patient declined a biopsy. Patient D had a growing lesion on serial CT scans and on FDG-PET the SUV was more than double that of the incident lesion (8.9 versus 4.3).
Upon reassessment by the thoracic surgeon, these four patients were now felt to be medically operable. Major pulmonary resection, consisting of lobectomy and nodal sampling, was undertaken for attempted surgical salvage (table 2) . Adhesions were found in all cases, and this was the most commonly described intraoperative finding attributable to the prior RT. Although in some cases these were simply dissected, they precluded the plan for a thoracoscopic resection in one case, requiring conversion into an open thoracotomy. In another patient, adhesion of lung to the overlying ribs required a partial chest wall resection. The duration of each surgery was within normal limits, and there were no significant intraoperative or post-operative complications.
Surgical pathology was re-reviewed by a single experienced thoracic pathologist. The resected tumour size was larger than the original lesion in each case with significant necrosis to varying degrees, reflecting at least a partial pathological response to the radiotherapy. In the three cases where viable cancer cells were found, the pathological subtype of residual NSCLC was identical to the originally treated lesion, although in the third case adenocarcinoma was located only in focal nests within the otherwise necrotic mass, accounting for only 5-10% of the resected tissue. Adequate surgical margins were achieved in all three of these cases. In the fourth case, the Our experience confirms the results of several large prospective trials demonstrating excellent local control of early-stage NSCLC with SBRT. We have also shown that carefully selected patients who do experience LF are able to safely and successfully undergo post-SBRT resection without significant surgical morbidity. Medical operability is not always fixed and constant as shown in these four cases, and surgical salvage should not be dismissed offhand in patients previously felt to be medically inoperable.
Presently, we are unable to accurately characterise the radiological changes seen following SBRT [3] , particularly at the site of treatment where marked inflammatory and fibrotic changes may resemble or obscure signs of recurrent disease [7] . Although a healthy level of clinical suspicion for recurrence should be maintained, false positives are possible (as in patient D) and the potential morbidity of unnecessary major surgery should be kept in mind.
The timeliness with which LF is identified are equally important. Patient B was closely monitored and investigated for several months prior to proceeding with surgery. Whether this delay in diagnosis had any clinical implication is uncertain. An earlier resection may potentially have caught the disease before it had spread to the mediastinal nodes.
At the other end of this spectrum, an adequate interval of time should be granted after SBRT prior to judging failure. Patient C's post-operative pathology report only revealed focal nests of adenocarcinoma within an otherwise necrotic mass. As it composed only 5-10% of the tumour volume, it would be difficult to attribute the doubling in tumour size observed on imaging to this low fraction of viable cancer alone. The natural course of these cancer cells, had they remained in situ, is unclear. Surgery was performed less than 1 yr after completion of SBRT and it is possible that these residual cancer cells may not have remained viable over longer follow-up. We do not feel that the pathological findings indicate a clear case of LF.
For patient A, the surgery was undertaken in a relatively timely manner, and the tumour was resected without complications. The patient remains alive and well nearly 2 yrs later without evidence of disease.
Closely coordinated care and multidisciplinary meetings are essential when deciding upon surgical salvage. Serial CT scans are often obtained in routine follow-up. Particular attention should be paid to the exact location of the recurrence in relation to the original tumour and if possible correlated to the dosimetric data from the radiotherapy plan. PET-CT scans are The gold standard remains tissue confirmation from the suspicious mass. However, the sensitivity in the context of the extensive fibrotic and/or necrotic changes from the high-dose SBRT is not entirely known, and in the case of patient B, pathological confirmation of recurrence only occurred after a total of 11 passes had been taken over three separate biopsy attempts. The procedure itself may be relatively contraindicated in patients with poor pulmonary status. As a result, careful consideration should go into the selection and planning of such procedures.
We have demonstrated that local failures following SBRT may be successfully and safely salvaged, particularly in the case of isolated local failures. Two recent reports from Japan demonstrated surgical salvage in patients who were initially medically operable but had refused surgery up-front [8, 9] . Our series demonstrates that surgical salvage may also be feasible in selected patients that were initially considered medically inoperable. Our experience would suggest that the optimal surgical approach for these patients should remain thoracotomy as opposed to video-assisted thoracoscopic surgery. The challenge remains in identifying those patients who truly have local failure in a timely manner. Careful patient selection combined with surgical expertise allows for successful salvage with minimal morbidity. Once again, close and regular follow-up as well as close cooperation between the appropriate medical disciplines is emphasised. Amyloidosis is characterised by the deposition of insoluble protein fibrils in organs and tissues, which leads to organ dysfunction. Amyloidosis is classified according to the composition and localisation of fibrils. The most frequent amyloidosis is immunoglobulin (Ig)-light-chain (AL) amyloidosis. In systemic AL amyloidosis, the fibrils are derived from circulating monoclonal light chains that are usually produced by intramedullary clonal plasma cells. Localised AL amyloidosis is most often identified in upper respiratory, urogenital and gastrointestinal tracts, in the skin and in the orbit. In such
